-
Mashup Score: 0Uncovering cancer’s secrets: could liquid biopsies and artificial intelligence hold the answers? | Future Oncology - 11 month(s) ago
Tweetable abstract How are #liquidbiopsies and #AI pushing us closer to the goal of early cancer detection for all? Plus, what more needs to be done to truly deciphers cancer’s secrets? Find out in this editorial by @JadeParkerB
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis | Future Oncology - 11 month(s) ago
Aim: To examine whether tumor-specific and tumor-agnostic oncology trials produce comparable estimates of objective response rate (ORR) in BRAF-altered cancers. Materials & methods: Electronic database searches were performed to identify phase I–III clinical trials testing tyrosine kinase inhibitors from 2000 to 2021. A random-effects model was used to pool ORRs. A total of 22 cohorts from five…
Source: Future OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
For BRAF-altered #cancer, tumor-agnostic clinical trials do not yield substantially different results from tumor-specific studies and may offer a more efficient method for efficacy across multiple tumor types simultaneously. https://t.co/ZmxOkEm68Z
-
-
Mashup Score: 3
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) unfit for hematopoietic stem cell transplantation have poor outcomes. Novel therapies that provide durable benefit with favorable tolerability and clinically meaningful improvement in survival are needed. T-cell immunoglobulin domain and mucin domain-3 (TIM-3) is an immuno-myeloid regulator…
Source: Future OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2 | Future Oncology https://t.co/qVXLj3s2Ju
-
-
Mashup Score: 3Relationships among clinicians are crucial to successful palliative care integration: a qualitative study in lung cancer | Future Oncology - 1 year(s) ago
Aims: Palliative care integration improves quality of life among patients with lung cancer and their families. Despite these benefits, significant barriers persist and patients do not receive timely integration. This study sought to identify facilitators of and barriers to integration in lung cancer care. Materials & methods: Semistructured qualitative interviews were conducted with palliative…
Source: Future OncologyCategories: Latest Headlines, PulmonologyTweet-
#Relationships among #clinicians are crucial to successful #PalliativeCare care integration: a #qualitative #study in #lungcancer https://t.co/qSwgN1zx6p https://t.co/UQ1cYglFCq
-
-
Mashup Score: 0TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors | Future Oncology - 1 year(s) ago
Crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer. However, unmet needs remain, including treatment of patients with resistance mutations, efficacy in brain metastasis and avoidance of neurological side effects. Taletrectinib was designed to: improve efficacy; overcome resistance to first-generation ROS1 inhibitors; and address brain…
Source: Future OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors | Future Oncology https://t.co/V1PxnXq8iR @MNagasaka @oncoOuLungCA @BenjaminBesseMD @MP_3855 @LuisERaez1 #lcsm
-
-
Mashup Score: 4Testing methods to diagnose TRK fusion cancer - a plain language summary and patient perspective | Future Oncology - 1 year(s) ago
What is this summary about? This is a plain language summary of a 2022 study published in Cancer Genetics. This study describes the different tests used to detect a rare type of cancer called TRK (tropomyosin receptor kinase) fusion cancer in people taking part in three clinical trials testing the medication larotrectinib. Larotrectinib targets TRK fusion proteins, abnormal proteins that result…
Source: Future OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
I was honored to be an author on this plain language summary about testing for #NTRK @alexdrilon @SusanNTRKers https://t.co/MIkGxK4yd3 https://t.co/YdMfUXeEqq
-
-
Mashup Score: 2
Invasive lobular carcinoma (ILC) is the most common histologic subtype of breast cancer after invasive ductal carcinoma (i.e., no special type [NST]). ILC differs from NST in clinical presentation, site-specific metastases and response to conventional therapies. Loss of E-cadherin protein expression, due to alterations in its encoding gene CDH1, is the most frequent oncogenic event in ILC….
Source: Future OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
The grant will help to perform correlative studies within the ROSALINE neoadjuvant investigator-initiatied study sponsored by @JulesBordet and enrolling patients with early invasive lobular carcinoma: https://t.co/o7boEoPRyp Well done Elisa 👏 👏 👏 #bcsm
-
-
Mashup Score: 0BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis | Future Oncology - 1 year(s) ago
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34+ MF cells. The oral MDM2 inhibitor navtemadlin (KRT-232)…
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Future Oncology @FutureOncol_FSG has recently published a Clinical Trial Protocol. This article provides details of the BOREAS study, investigating the MDM2 inhibitor navtemadlin in relapsed/refractory #myelofibrosis. Find out more here >>> https://t.co/Hxg4Yx1suF
-
-
Mashup Score: 14The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial | Future Oncology - 1 year(s) ago
, John MarquartDepartment of Surgery, Medical College of Wisconsin, 999 North 92nd Street, Suite CCC 320, Milwaukee, WI 53226, USA, Timothée Olivier https://orcid.org/0000-0002-6936-5783Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205, Geneva, SwitzerlandDepartment of Epidemiology & Biostatistics, University of California San Francisco, 550 16th St, 2nd…
Source: Future OncologyCategories: Expert Picks, Latest HeadlinesTweet-
Important new paper by L.Powell Here, we design, and describe a pragmatic, tumor agnostic trial of metastasectomy. Will interest anyone who cares about RCTs, interaction testing, or metastasectomy https://t.co/Lm2FUgimRF @vkprasadlab https://t.co/OKOPs9o6n2
-
-
Mashup Score: 0Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings | Future Oncology - 1 year(s) ago
Aim: To describe burden of chemotherapy-induced myelosuppression among chemotherapy-treated patients with extensive-stage small cell lung cancer (ES-SCLC). Materials & methods: Occurrence of grade ≥3 myelosuppressive hematological adverse events (HAEs), treatment patterns and healthcare resource utilization (HCRU) after chemotherapy initiation were evaluated using data from The US Oncology…
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An article from our partner journal @FutureOncol_FSG has highlighted that there is an unmet need to prevent & proactively manage chemotherapy-induced #myelosuppression. Read the full article >>> https://t.co/reFW4n0bg8 #LCAM #LCSM https://t.co/7J39nCcJGn
-
How are #liquidbiopsies and #AI pushing us closer to the goal of early cancer detection for all? Plus, what more needs to be done to truly deciphers cancer's secrets? Find out in this editorial by @JadeParkerB https://t.co/w8NULMXzOV